Literature DB >> 16787878

Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.

Masaki Yamaguchi1, Takeharu Kotani, Yoshihisa Nakamura, Mikio Ueda.   

Abstract

We report a case of refractory peripheral T-cell lymphoma (PTCL) successfully treated with a combination of fludarabine and cyclophosphamide (FLU/CY). A 68-year-old man with concurrent PTCL and diffuse large B-cell lymphoma was treated effectively with 3-course CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy, but PTCL relapse occurred and was resistant to ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) therapy. FLU/CY therapy led to complete remission, which was maintained for almost 14 months after a single course. We concluded that a FLU/CY regimen may be useful for attaining long-term remission in patients with refractory relapsed PTCL and should therefore be considered a valuable treatment choice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16787878     DOI: 10.1532/IJH97.05188

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  28 in total

1.  Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders.

Authors:  R Frewin; D Turner; M Tighe; S Davies; S Rule; S Johnson
Journal:  Br J Haematol       Date:  1999-03       Impact factor: 6.998

2.  Subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine.

Authors:  R S Go; H Gazelka; J D Hogan; S M Wester
Journal:  Ann Hematol       Date:  2003-03-18       Impact factor: 3.673

3.  A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.

Authors:  J J Scarisbrick; F J Child; A Clift; R Sabroe; S J Whittaker; M Spittle; R Russell-Jones
Journal:  Br J Dermatol       Date:  2001-05       Impact factor: 9.302

4.  Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.

Authors:  J R Redman; F Cabanillas; W S Velasquez; P McLaughlin; F B Hagemeister; F Swan; M A Rodriguez; W K Plunkett; M J Keating
Journal:  J Clin Oncol       Date:  1992-05       Impact factor: 44.544

5.  Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine.

Authors:  S T Ong; H Koeppen; R A Larson; O I Olopade
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

6.  Peripheral T-cell lymphoma.

Authors:  J O Armitage; J P Greer; A M Levine; D D Weisenburger; S C Formenti; M Bast; S Conley; J Pierson; J Linder; J B Cousar
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

7.  Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.

Authors:  T E Witzig; J J Weitz; J H Lundberg; A Tefferi
Journal:  Leuk Lymphoma       Date:  1994-06

8.  Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.

Authors:  J O Armitage; J M Vose; J Linder; D Weisenburger; D Harrington; J Casey; P Bierman; S Sorensen; M Hutchins; D F Moravec
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

9.  Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

Authors:  K R Rai; B L Peterson; F R Appelbaum; J Kolitz; L Elias; L Shepherd; J Hines; G A Threatte; R A Larson; B D Cheson; C A Schiffer
Journal:  N Engl J Med       Date:  2000-12-14       Impact factor: 91.245

10.  High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies.

Authors:  E Van Den Neste; L Michaux; N Layios; S Costantini; J Francart; C Lambert; A Sonet; M André; A Robert; A Ferrant
Journal:  Ann Hematol       Date:  2004-03-16       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.